Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Handa Oncology receives FDA final approval for Omcazio (cabozantinib) across multiple oncology indications including renal cell carcinoma
Small molecule, cancer, tyrosine kinase inhibitor, renal cell carcinoma, hepatocellular carcinoma, neuroendocrine tumors - Read more

EnterpriseSG launches Boston biotech hub in Kendall Square, targeting life sciences partnerships with Massachusetts firms
Government trade hub, life sciences, biotech, venture capital, AI/ML - Read more

Argonaut Manufacturing Services divests life sciences, diagnostics unit to 1315 Capital, forming Aluris Sciences
Divestiture, manufacturing, biologics, fill-finish, private equity - Read more

Bionova Scientific, Minaris partner to expand plasmid DNA supply for cell and gene therapy manufacturing
Manufacturing agreement, cell therapy, gene therapy, plasmid DNA, CDMO - Read more

Exegenesis Bio, Modalis Therapeutics collaborate to advance MDL-201 gene therapy for Duchenne muscular dystrophy
Research collaboration, rare disease, gene therapy, CRISPR, epigenome editing - Read more

IMUNON, National Cancer Institute enter CRADA to advance IMNN-001 clinical development across solid tumor indications
Research collaboration, oncology, gene therapy, immunotherapy, drug discovery - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Bionyra Pharma doses first healthy volunteers in Ph1 study of BYN-001 (anti-IL-25) for atopic dermatitis
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, IL-25, type 2 inflammation - Read more

Shilpa CDMO launches at CPHI Milan as dedicated complex small-molecule contract development and manufacturing brand
Small molecule, oncology, operational, strategic - Read more

Champions Oncology reports Q1 fiscal 2027 revenue of $15.2M, up 8.8% year over year
Translational research services, oncology, financial, operational - Read more

Yarrow Bioscience prices $150M public offering to fund autoimmune thyroid disease R&D
Autoimmune, thyroid disease, clinical-stage - Read more

Graph AI raises $13.3M Series A to scale AI-native patient safety platform for pharma
AI/ML platform, pharmacovigilance, software platform, patient safety - Read more

Tempest Therapeutics plans $7.5M private placement for working capital, general corporate purposes
Clinical-stage, cell therapy, cancer, autoimmune, in vivo CAR-T - Read more

FDA oncology chief Angelo de Claro vows to continue OCE innovation, integrate AI into regulatory reviews
Oncology, regulatory, operational, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA delays decision on Exelixis' zanzalintinib plus Roche's Tecentriq (atezolizumab) for metastatic colorectal cancer to March 2026
Small molecule, cancer, kinase inhibitor, colorectal cancer, combination therapy, PD-L1 - Read more

FDA issues complete response letter to Seikagaku for SI-6603 (condoliase) biologics license application over manufacturing deficiencies
Protein therapy, musculoskeletal, enzyme, condoliase, lumbar disc herniation, complete response letter - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here